A new study has shown that the intranasal COVID-19 vaccine being developed by University of Pittsburgh School of Medicine works against variants in animals. The study, published in the journal Science, shows that the vaccine is effective in protecting against both the original SARS-CoV-2 virus and two variants that have emerged since the pandemic began.
The intranasal vaccine is being developed as a needle-free alternative to traditional injectable vaccines. It is administered using a nasal sprayer and has been shown to be safe and effective in animal studies.
The new study shows that the vaccine protects against both the original SARS-CoV-2 virus and two variants that have emerged since the pandemic began. The two variants, dubbed B.1.1.7 and B.1.351, are thought to be more contagious than the original virus and have been associated with increased severity of disease.
The study used a mouse model to test the vaccine’s efficacy against the two variants. Mice that were vaccinated with the intranasal vaccine were protected against both variants, while mice that were not vaccinated were infected with both variants.
The findings suggest that the intranasal vaccine is effective against both the original SARS-CoV-2 virus and variants. The vaccine is currently in clinical trials and, if proven effective, could be an important tool in the fight against COVID-19.
Much of the world is still in the grip of the COVID-19 pandemic, with new variants of the virus continuing to emerge. There is an urgent need for vaccines that can protect against these variants.
Now, a team of researchers has developed an intranasal vaccine that is effective against two of the most common variants, known as B.1.1.7 and B.1.351. The vaccine was tested in animals and found to provide significant protection against both variants.
The intranasal vaccine is based on a type of vaccine known as a live-attenuated virus vaccine. This type of vaccine uses a weakened form of the virus to stimulate the immune system. The weakened virus is unable to cause disease.
The vaccine was developed by a team at the University of Wisconsin-Madison. It is based on a vaccine that was previously developed for influenza.
The team tested the vaccine in mice and ferrets. These animals are often used in research because they are susceptible to the same viruses as humans.
The vaccine was found to be highly effective in both animals. It induced a strong immune response and provided significant protection against the two variants.
The findings suggest that the vaccine could be an effective way to protect against the B.1.1.7 and B.1.351 variants. However, further research is needed to confirm this.
The vaccine is not yet available for use in humans. However, the findings provide hope that a safe and effective vaccine against COVID-19 could be available in the near future.
